Avastin decreases PCV symptoms

Article

Intravitreal injections of bevacizumab (Avastin; Genentech) stabilize vision and decrease retinal detachment in patients with polypoidal choroidal vasculopathy (PCV), according to a study published in the May 2008 issue of the British Journal of Ophthalmology.

Intravitreal injections of bevacizumab (Avastin; Genentech) stabilize vision and decrease retinal detachment in patients with polypoidal choroidal vasculopathy (PCV), according to a study published in the May 2008 issue of the British Journal of Ophthalmology.

Timothy Y. Y. Lai of the department of ophthalmology and visual sciences at the Chinese University of Hong Kong and colleagues conducted a retrospective review of 15 patients (15 eyes) with symptomatic PCV. At baseline, mean best-corrected visual acuity (BCVA) was 0.61 and mean central foveal thickness (CFT) was 347 µm. Subjects received monthly injections of bevacizumab for a three-month period. Mean follow-up was 12.8 months; persistent or recurrent symptoms (subretinal fluid and polypoidal lesions) received further treatment with bevacizumab and/or with verteporfin photodynamic therapy (PDT).

After the initial three months, although mean BCVA improved to 0.51 and mean CFT decreased to 247 µm, polyps remained present in all eyes. Mean BCVA remained stable at 0.51 after follow-up; subjects who had undergone PDT were found to be less likely to have persistent lesions.

The researchers concluded that bevacizumab monotherapy can stabilize vision and improve anatomical factors in PCV, but that adjunctive PDT therapy is necessary for polypoidal lesion regression.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Related Content
© 2025 MJH Life Sciences

All rights reserved.